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Abstract
Context Treatment burden, the burden associated with the treatment
and management of chronic illness, has not yet been well articulated.
Objective Using Rodgers’ (1989, Journal of Advanced Nursing, 14,
330–335) method of concept analysis, this review describes the
ways in which treatment burden has been conceptualized to deﬁne
the concept and to develop a framework for understanding its
attributes, antecedents and consequences.
Methods Leading databases were searched electronically between
the years 2002 and 2011. To ensure the review focused on actual
observations of the concept of interest, articles that did not mea-
sure treatment burden (either qualitatively or quantitatively) were
excluded. An inductive approach was used to identify themes
related to the concept of treatment burden.
Main results Thirty articles, identiﬁed from 1557 abstracts, were
included in the review. The attributes of treatment burden include
burden as a dynamic process, as a multidimensional concept, and
comprising of both subjective and objective elements. Prominent
predisposing factors (antecedents) include the person’s age and
gender, their family circumstances, possible comorbidity, high use
of medications, characteristics of treatment and their relationship
with their health-care provider. The most dominant consequences
are poor health and well-being, non-adherence to treatment, inef-
fective resource use and burden on signiﬁcant others. Furthermore,
many of these consequences can also become antecedents, reﬂect-
ing the cyclic and dynamic nature of treatment burden.
Conclusion The ﬁndings underscore the need for researchers and
health-care professionals to engage in collaborative discussions and
make cooperative eﬀorts to help alleviate treatment burden and tai-
lor treatment regimens to the realities of people’s daily lives.
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Introduction
Chronic diseases are the leading cause of death
in the world, largely associated with 63% of
the 57 million deaths that occurred in 2008.1
The majority of these deaths are attributed to
cardiovascular diseases, cancers, chronic respi-
ratory diseases and diabetes.1 Although the
burden associated with chronic illness is well
documented, the burden associated with the
treatment and management of chronic illness
has not been well deﬁned. Related terms such
as disease burden and symptom burden have
been well articulated,2,3 but the deﬁnition of
treatment burden has remained elusive and
confusing. Although treatment burden is often
inseparable from disease burden, it is not based
on the natural history of the disease, but on
the need to treat the disease in order to change
its course or ameliorate its eﬀects. Treatment
burden is, therefore, an important concept that
is distinct from disease burden, symptom bur-
den and other related terms.
Treatment of chronic illness comes in many
forms including surgery, physical therapy, psy-
chological therapy and radiotherapy. However,
one of the most common treatment forms is
the use of medication. In Australia, as in many
developed nations, the use of medications rep-
resents one of the largest components of health
expenditure; accounting for 13% of the total
health expenditure in 2006–07.4 There were 262
million prescriptions ﬁlled in 2008,4 many of
which were used to treat chronic illness. The
prevention and treatment of chronic illness,
especially when involving multiple medications,
can become burdensome.
Few validated instruments have been devel-
oped to assess the experiences of treatment bur-
den on patients.5–16 In some cases however, the
concept of treatment burden has been included
as one domain within a multidimensional
instrument designed to assess health-related
quality of life or treatment satisfaction.5–12,17,18
These measures reﬂect wide variation in terms
of the dimensions of treatment burden and its
deﬁnition. One team of researchers explored the
experience of treatment burden with the
purpose of identifying its core components.19
These researchers identiﬁed four main tasks that
contributed to the sense of burden, namely
learning about treatments and their conse-
quences, engaging with others and mobilizing
support, adhering to treatment and lifestyle
changes and monitoring treatments. Although
the most useful conceptualization of treatment
burden in the literature, this analysis was not
intended to provide a concept analysis. Instead,
it was focused on the utility of an existing theo-
retical framework as a tool for identifying bur-
den. Thus, it is important to conduct further
empirical investigation of this concept to
enhance our knowledge and draw coherent con-
clusions about its prevalence and impact.
The lack of a clear conceptual model of
treatment burden has contributed to our inabil-
ity to measure its impact or identify people
most at risk, thereby obscuring the health pro-
fessional’s role in assisting people to alleviate
this burden. It has generated confusion and
misinterpretation that detracts from appropri-
ate and timely management or prevention. A
crucial ﬁrst step in assessing treatment burden
and articulating the role of health professionals
is deﬁning the concept itself and developing a
framework for understanding its occurrence
and impact.
The purpose of this review is to comprehen-
sively analyse the concept of treatment burden
to enable informed recommendations for
health professionals who wish to alleviate its
impact. This analysis aims to outline the ways
in which treatment burden has been conceptu-
alized and operationalized, by identifying and
discussing the critical attributes of treatment
burden, exploring the factors that can lead to
treatment burden (antecedents) and highlight-
ing its consequences. Antecedents are predis-
posing events that occur prior to the concept,
whereas consequences are events that occur as
a result of the concept.20 Furthermore, attri-
butes are at the heart of a concept, providing
insight into its occurrence.20 A thorough
knowledge of the attributes, antecedents and
consequences of treatment burden is important
from a health practice perspective because
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without such knowledge, health professionals
will not be able to provide services that allevi-
ate such burden among people with chronic
illness.
Methods
Rodgers’21 evolutionary method of concept
analysis was used to comprehensively analyse
the concept of treatment burden. This particu-
lar method is well suited to the concept of
treatment burden because of its changing and
dynamic nature (e.g. the emergence of new
health technologies leading to possible burden).
The evolutionary view of concept analysis indi-
cates that concepts are inﬂuenced by contextual
factors and may change over time.22
Data sources and search strategy
A systematic search was conducted using the
terms ‘treatment burden’, ‘burden of treat-
ment’, ‘medication burden’ and ‘burden of
medication’ as keywords in the following data-
bases: Medline, PsychINFO, Cinahl, Cochrane,
Scopus, Health Reference Centre (HRC),
PsychEXTRA, Informit, the System for Infor-
mation on Grey Literature in Europe (SIGLE)
and National Technical Information Service
USA (NTIS). A sensitivity analysis conducted
prior to the search suggested that these key
search terms encompassed most of the research
within the ﬁeld. In particular, the sensitivity
analysis conﬁrmed that medication was the
most prominent form of treatment for chronic
illness, necessitating the inclusion of this search
term. Although the use of broader terminology
may have identiﬁed other bodies of literature,
restricting the search to these speciﬁc terms
ensured that the overlap with other forms of
burden was minimized.
To ensure a contemporary exploration of
this concept, the search was limited to articles
published from 2002 to 2011 with human sub-
jects and a focus on the major chronic illnesses
that have been named as priorities in Australia:
asthma, diabetes, cardiovascular disease, mus-
culoskeletal illness, cancer and mental health.
According to the World Health Organization,
these conditions contribute a signiﬁcant burden
in terms of mortality and/or morbidity glob-
ally.1 After this search, 1157 abstracts were
identiﬁed.
These abstracts were reviewed by two mem-
bers of the research team. Abstracts without a
substantial focus on treatment burden were
excluded, along with those that emphasized
disease or symptom burden. If both researchers
were uncertain about whether the abstract met
the inclusion criteria or were not in agreement,
the full article was retrieved and reviewed. As
a result of this process, 170 articles were thor-
oughly reviewed by two researchers, leading to
the exclusion of a further 140 articles (Fig. 1).
Further exclusions were applied to ensure the
review focused on articles that actually mea-
sured a person’s experience of treatment bur-
den. Speciﬁcally, articles that did not measure
treatment burden (either qualitatively or quan-
titatively) were excluded (i.e. opinion pieces or
theoretical articles). Thirty articles met the
inclusion criteria and were included in the con-
cept analysis (Table 1). Most of these studies
Initial search 
(n = 1157) 
Records screened  
(n = 1157) 
Full-text articles 
assessed for eligibility  
(n = 170) 
Full-text articles 
excluded  
(n = 140)               
Records excluded  
(n = 987) 
Full text empirical studies 
included in concept analysis  
(n = 30) 
Searches via databases
Cochrane (n = 129)            
Ovid Medline (n = 346)
Psych Extra (n = 1)             
PsychInfo  (n = 85)             
HRC   (n = 245 )                 
Informit (n = 1)                   
Scopus (n = 304)                
Cinahl (n = 42) 
SIGLE (n = 4) 
NTIS (n = 0) 
Figure 1 Selection process for concept analysis
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were conducted in the United States of Amer-
ica (USA) and included self-report survey ques-
tionnaires to assess the level of treatment
burden among patients and their carers. A
number of inter-related themes were identiﬁed
from the review relating to the antecedents,
attributes and consequences of treatment
burden.
Data extraction and analysis
An initial coding framework was developed
based on the questions in Table 2. These ques-
tions reﬂected Rodgers’ method of concept anal-
ysis, which involves a multidisciplinary literature
review to identify the common attributes, ante-
cedents and consequences of the concept.3
Table 1 Articles included in the concept analysis
Reference Country Participants Data collection methods
Anderson et al.5 USA n = 170 and n = 402, people with diabetes Mixed methods
Fried et al.51 USA n = 125, 65 years or older with a limited
life expectancy
Quantitative survey
Kim et al.27 USA n = 1083, male and female with schizophrenia Quantitative survey
Brod et al.8 Multination n = 17,488 with type 2 diabetes Quantitative survey
Gallacher et al.19 UK n = 47 patients with chronic heart failure Qualitative interview
Henry et al.40 USA n = 15,532 people with cancer Quantitative survey
Campbell et al.9 UK n = 19 with asthma for focus groups, n = 131
for questionnaire
Mixed methods
Vijan et al.37 USA n = 1,653 Veteran patients with type 2 diabetes Quantitative survey
Benner et al.45 USA n = 5759 patients with initiated antihypertensive
lipid-lowering therapy
Quantitative survey
Bernhard et al.13 Switzerland/
Italy
n = 249 patients in a trial for the prophylaxis
for delayed emesis
Quantitative survey
and diary cards
Ribi et al.16 Switzerland n = 373 women with early or advanced breast cancer Quantitative survey
Yoon et al.47 USA n = 1,219 women with breast cancer Quantitative survey
Ow33 Singapore n = 22 parents from 20 families with children
with childhood cancer
Quantitative survey
Zucca et al.35 Australia n = 1410 adults with cancer Quantitative survey
Graves et al.24 USA n = 101 primary caregivers of children with asthma Quantitative survey
Olinder et al.48 Sweden n = 90 adolescents aged 12–18 years with diabetes Diary records and survey
Haugstvedt et al.41 Norway n = 103 (mothers) and n = 97 (fathers) of
115 children with type 1 diabetes
Quantitative survey and
medical records
Thomas31 USA/France n = 1500 patients with schizophrenia (Study 1)
and n = 284 (Study 2)
Quantitative survey
Wysoci & Gavin44 USA n = 190 adult couple caregivers of a child
with a chronic condition
Quantitative survey
Martire et al.42 USA n = 244 dyads with a major depressive disorder Quantitative survey
Longo et al.34 Canada n = 282 patients with cancer Quantitative survey
Rodbard et al.26 USA n = 3551 individuals with type 2 diabetes mellitus Quantitative survey
Brod et al.23 Australia/NZ n = 299 male or female with type 1 diabetes Quantitative survey
Fiese et al.25 USA n = 153 families of a child with asthma. Quantitative survey
Nicholl et al.36 USA n = 970 with recent schizophrenia and
2996 with ongoing schizophrenia.
Medical claims
Tija et al.32 USA n = 457 women (60–65 years) eligible
for breast cancer chemotherapy
Quantitative survey
de Kraker et al.43 Multination n = 410 patients between ages 6 months
and 18 years with Wilms’ tumour
Medical outcomes
Gutierrez-Maldonado
et al.28
Chile n = 45 caregivers of people with schizophrenia Quantitative survey
Moss & Crane29 USA n = 86 older women with post-myocardial infarction Quantitative survey
Ziaian et al.38 Australia n = 160 children aged 10–16 years with a chronic illness Quantitative survey
ª 2013 Blackwell Publishing Ltd
Health Expectations, 18, pp.312–324
Literature review of treatment burden, A Sav et al. 315
Five researchers independently extracted data
from the selected articles in accordance with the
review questions in Table 2 and coded the data
within the initial framework, expanding the
subthemes as required. Each coding framework
was then reviewed by two researchers for recur-
ring themes, which were placed into categories
(attributes, antecedents, and consequences).
Results
Attributes of treatment burden
The deﬁning attributes of treatment burden
were chosen due to their frequent occurrence in
the literature. Treatment burden emerged as a
dynamic multidimensional concept that com-
prised of both subjective and objective elements.
A dynamic process
Treatment burden changed over time23 in
response to disease severity and control24,25
and the development of comorbidities.26,27 It is
possible that that either familiarity with, or
acceptance of, treatment lessens the experience
of burden through a process of adjustment. In
patients with diabetes, longer duration of dis-
ease was associated with less burden.8 Despite
changing over time, some degree of burden
appeared to persist.28 Treatment burden also
had a cyclic aspect, with many of the conse-
quences of treatment burden also being ante-
cedents. For example, increased burden could
result in non-adherence to medication which
may then lead to further burden.29
A multidimensional concept
Treatment burden emerged as a multidimen-
sional concept, including physical, ﬁnancial,
temporal, and psychosocial time demands.
Physical side-eﬀects30 were a signiﬁcant
source of treatment burden,13,24,29,31 arising in
particular from medications or drug interac-
tions.29 Side-eﬀects could occur at any stage of
treatment. For example, they could be more
acute at the commencement of therapy, they
could be ongoing or they may result from
cumulative toxicity in the later stages of treat-
ment.29 Side-eﬀects varied in nature and sever-
ity, from minor hypoglycaemic events and
weight gain,8 to those that are so unpleasant
that the possibility of experiencing them fright-
ened some patients.8 Experiencing more than
one side-eﬀect contributed to overall treatment
burden.13 Some side-eﬀects may be preventable
especially those related to the use of medica-
tions that were no longer required.32
The cost of treatment could be high,24 con-
tributing to overall treatment burden.28,29,33
Even when treatment was subsidized, the out-
of-pocket costs could be intolerable.34 The cost
of travel was one of the greatest out-of-pocket
expenses, especially for patients from non-
metropolitan areas,35 although this was often
obscured by the rhetoric of ‘free’ hospital care.
Inpatient treatment was also associated with
ﬁnancial burden.36 Personal medical costs com-
peted with other living expenses, such as, food,
clothing and housing.26
The time required to plan and organize tra-
vel for treatment,37 receive treatment,19,35,38
learn about treatments and their potential out-
comes,19 monitor treatment37,39 and manage
side-eﬀects40 was related to treatment burden.
As well as consuming ﬁnancial resources, travel
required a great deal of time, especially for
patients who lived in outer regional areas.35 A
substantial time burden for family and carers
as well as for patients themselves was evident.40
One study reported families of children with
chronic illnesses may already be under consid-
erable time pressure, and the increased use of
long-term home-based care for these children
adds to this burden over time.38
The psychological and social aspects of treat-
ment burden were closely linked, often because
additional support is needed to manage treat-
ment28 or day-to-day tasks or both. Some
Table 2 Review questions for data extraction
Number Review questions
1 What are the key attributes of the concept?
2 Which factors (antecedents) are proposed to
precede treatment burden?
3 What are the consequences of treatment burden?
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patients had diﬃculties managing home
responsibilities as a consequence of treat-
ment,33,35,40 and often, household and personal
tasks, normally completed by the patient, were
carried out by other family members.34 Parents
needed to accompany, administer medication
to and monitor a child receiving treatment.
However, many families seemed to adapt well
to treatment tasks.41 When children attended
school, the burden of administering medica-
tions was likely to be borne by the child or a
staﬀ member, which may explain why some
children experience more burden than their
parents.38 Older adults generally relied on fam-
ily for assistance and support.42 Family mem-
bers or carers also at times needed to
accompany or support patients receiving inva-
sive or lengthy treatments such as cancer treat-
ment.40 The impact of treatment on signiﬁcant
others added to the burden experienced by the
patient.43 Family members could perceive
themselves as being incompetent or not able to
care for the patient due to a lack of personal
or economic resources.28 These perceptions
could also add to the patient’s sense of bur-
den.28 Thus, there is a need for adequate infor-
mation to be provided by health-care
professionals about treatment and its conse-
quences in order to address these perceptions.33
Treatment tasks that interfered with daily
activities24 or lifestyle5,41,43also contributed to
treatment burden.36,41 For instance, it was
inconvenient to transport treatment equipment
or medications (e.g. insulin injections or
metered dose inhalers) and embarrassing to use
(medication) in public.9 More invasive treat-
ments such as dialysis were even more inconve-
nient and restrictive.5,9 Interestingly, new
technologies (e.g. new forms of blood glucose
monitoring) did not emerge as a signiﬁcant
source of distress or burden,44 but this area
requires further investigation.
Both subjective and objective burden
Some elements of treatment burden such as the
number of medications,19,24,29,32,36,45,46 and time
to administer or monitor treatment,19 could be
measured objectively. Patients and carers,
however, were not homogenous and therefore
could have diﬀerent perceptions concerning the
burden related to similar tasks.38 This subjective
aspect of treatment burden was associated with
a number of factors13,24,43 and therefore may be
predictable. However, as it includes elements of
an intangible nature, for example, guilt, hope-
lessness, and fear,33 its quantiﬁcation could be
diﬃcult. Subjective aspects, such as fear of med-
ication supply running out, the meaning attrib-
uted to side-eﬀects,16 beliefs about a
medication’s eﬀectiveness31,32 and beliefs about
the impact of medication on health and well-
being (e.g. believing that medication is harmful
and addictive), were associated with increased
levels of treatment burden.9
Antecedents of treatment burden
Although a large number of antecedents of
treatment burden were identiﬁed, there was
minimal information about their particular
inﬂuence on treatment burden, reﬂecting the
lack of theoretical development within the
research ﬁeld. Antecedents were associated with
characteristics of the patient, the disease, the
treatment, the family or support network and
the health-care system.
Patient characteristics
Gender seemed to be a key antecedent of bur-
den because men and women experienced treat-
ment burden diﬀerently. Women experienced
more treatment burden than men and also
reported more caregiver burden when their chil-
dren were sick, possibly as a result of their tra-
ditional homemaker roles.13,40,41 A strong
positive correlation was apparent between
unemployment and treatment burden.35,40 A
strong relationship between age and treatment
burden also emerged.16,40,47 Elderly people
seemed to experience more treatment burden
than young people, as might be expected given
the likelihood of illness and multiple conditions.
Disease conditions
As expected, comorbidity was associated with
increased burden.26 The presence of particular
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comorbidities,27,36 especially psychological ill-
nesses such as anxiety or depression,40 was
associated with high levels of treatment bur-
den.28,36,37 Particular chronic conditions such
as diabetes37 and schizophrenia36 were associ-
ated with greater levels of treatment burden.
Finally, functional capacity, poor symptom
control24 and longer duration of illness8 could
also lead to treatment burden.39
Treatment characteristics
Treatment characteristics, particularly medica-
tions,8,13,31 were an important antecedent of
burden. Using a high number of medica-
tions19,24,29,32,45,46 emerged as the most com-
mon antecedent in the literature. Particular
dosage forms (e.g. injections as opposed to oral
tablets) were also considered to be burden-
some. Finally, changes to medication regimens
were also a key antecedent of burden and have
been attributed to a lack of continuity of
health care.19
Family support and engagement
Availability of extended family networks and
support from an appropriate social network
could lead to lower treatment burden.33 How-
ever, the support and assistance provided by a
caregiver could also result in treatment burden
for both the patient and the carer.28 One way
of reducing burden, particularly for carers, was
to introduce an intervention designed to sup-
port family members to understand, communi-
cate and participate in treatment decisions.28
Health-care systems
An aspect of health care that emerged fre-
quently was the health practitioner–patient
relationship.29,37 Failure of health-care practi-
tioners to provide adequate information
regarding treatment was associated with treat-
ment burden.37 Poor communication between
patients and health-care providers about medi-
cation adherence was likely to result in the use
of multiple medications (polypharmacy), which
was associated with treatment burden.29 The
location of the health-care centre also emerged
as an antecedent of ﬁnancial and time burden,
caused by long travel distances.35 This issue
was further complicated by a lack of ﬁnancial
reimbursement for travel of this kind.35
Consequences of treatment burden
The concept analysis identiﬁed a number of
consequences of treatment burden including
poor adherence, reduced health and well-being,
ineﬀective use of health resources, reduced
employment and low productivity, and nega-
tive health impacts on family and carers.
Adherence
One of the most widely cited consequences of
treatment burden was non-adherence to treat-
ment. Non-adherence19,27,37,48 was then related
to sub-optimal health outcomes,29,37 including
disease relapse,31,36 decreased quality of life24
and the unscheduled use of more expensive
health-care resources, such as increased emer-
gency department visits and hospitalization.31
Non-adherence was also associated with
increased school absences.24
Non-adherence was most often linked to
treatment burden resulting from medication
characteristics, including the number of medi-
cations, their frequency of administration,45
side-eﬀects24 and perceived lack of eﬃcacy.24
As the number of medications being used
increased, the rate of non-adherence associated
with the addition of each additional medication
decreased.45 Hence, there appeared to be a
threshold of treatment burden where additional
medications did not add further burden. How-
ever, the addition of each additional medica-
tion did nevertheless add to the ﬁnancial cost
of treatment.27 This was a concerning ﬁnding
given that the elderly and welfare recipients
were found to reduce their use of medications
in response to the introduction of prescription
co-payments and subsequently experienced an
increase in serious adverse events.34
Health and well-being
The health and well-being consequences of
treatment burden were many and varied. Treat-
ment burden aﬀected patient choices about
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treatment,37 with some patients who were rec-
ommended insulin refusing this therapy.37 Such
a choice was associated with poor glycemic
control.37 However, opting for a less-eﬃcacious
alternative treatment could be a reasonable
course of action given that ‘…diﬃcult or
demanding treatment regimens may apprecia-
bly lower treatment eﬀectiveness, which may be
possible to achieve with less burdensome treat-
ment’.5:573 In other words, while a treatment
might appear to have superior eﬃcacy in the
controlled setting of a clinical trial, in reality,
the interaction between treatment regimen and
treatment burden could create diﬃculties.
Thus, patients may choose to select a less eﬀec-
tive, but less burdensome treatment to suit
their daily lives, which ultimately may result in
better health outcomes.
Treatment burden was associated with a
number of negative health outcomes including
speciﬁc symptoms,16,29 recurrence of dis-
ease,28,36,43 decline in health,29,36 reduced sur-
vival,43 decreased treatment satisfaction23 and
reduced quality of life.25,40 Treatment-related
side-eﬀects were often found to have a marked
impact on quality of life,16 which was also
aﬀected by perceived treatment burden, disease
severity25 and disruption of lifestyle.48 Finally,
as well as increasing the risk of adverse out-
comes, which was mediated by non-adherence,
greater prescription co-payment burden was
associated with increased self-reported psycho-
logical distress and attempted suicide in
patients with schizophrenia.27
Resource use
Ineﬀective use of resources has been attributed
to treatment burden.19 Unfortunately, a reduc-
tion in scheduled care (i.e. non-adherence) may
result in a demand for unscheduled care (i.e.
hospital admission), creating avoidable
resource use.24,31 Perceived ﬁnancial burden
caused by prescription co-payments resulted in
the increased self-reported use of unscheduled
care, such as emergency room visits and hospi-
talization.27 Polypharmacy complicated therapy
and health-care delivery,29 which added to
unnecessary use of resources. Moreover, poly-
pharmacy was accompanied by an increased
risk that medications included in the treatment
regimen were unnecessary and therefore a
waste of resources.32
Employment
The burden of treatment had a marked impact
on the patient’s ability to attend work and
maintain productivity. In a cancer clinic,
patients who were still employed were absent
for an average of 12.6 days during the
month.34 Absences from work were related to
prescription co-payment burden,27 the need to
travel35 and side-eﬀects,34,40 including fatigue
associated with chemotherapy. The latter
resulted in the loss of 4.2 sick or vacation days
per month.40 In some instances, patients
needed to change employment status in order
to manage treatment burden.34,40 Caregivers
also needed to take time oﬀ work to care for
cancer patients.34 Unfortunately, work
absences could lead to feelings of guilt among
patients about burdening their co-workers and
lost productivity,40 which added to burden.
Family and carers
Treatment burden was related to carer burden
and fatigue,43 causing patients to forgo care-
giver support.34 The distress caused by treat-
ment burden was found to ﬂow in both
directions in that seeing a signiﬁcant other (i.e.
patient or carer) suﬀer could lead to further
burden and distress,42 especially in the case of
parents.25,41 There was evidence that eﬀective
treatment of a loved one resulted in signiﬁcant
beneﬁts for carers.42
Discussion
This concept analysis provides a much needed
theoretical framework for understanding the
dynamic, multidimensional and cyclic nature of
treatment burden. We found that treatment
burden is a dynamic process, evolving with the
emergence of new treatment options and symp-
toms. It persisted over time, but perhaps
reached a subjective threshold beyond which
perceptions of burden no longer increase. The
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dimensions of treatment burden include
undesirable physical eﬀects of treatment (side-
eﬀects), the economic burden imposed by treat-
ment (ﬁnancial burden), time required to
obtain, administer and manage treatment (time
burden), and the psychosocial aspects of bur-
den including the impact on family and lifestyle
(personal burden). Treatment burden has both
subjective and objective elements including
number of medications, time to administer and
monitor treatment (objective) vs. feelings of
guilt, hopelessness and fear relating to treat-
ment (subjective). A range of antecedents and
consequences were identiﬁed, although many
of the consequences could also become ante-
cedents, reﬂecting the cyclic nature of treat-
ment burden. The attributes, antecedents and
consequences emerging from the review of
treatment burden are summarized in Fig. 2,
which also highlights the cyclic nature of the
concept. As an outcome of this concept analy-
sis, we deﬁne treatment burden as a person’s
subjective and objective overall estimation of
the dynamic and multidimensional burden that
their treatment regimen for chronic illness has
imposed on them and on their family members.
It is inﬂuenced by a person’s characteristics,
disease duration/severity, treatment circum-
stances, level of family support and engage-
ment and also the overall health-care systems,
in which the person obtains treatment.
The health consequences of treatment bur-
den are particularly concerning given that
treatment burden has been associated with spe-
ciﬁc symptoms, recurrence of disease, decline
in health, reduced survival, decreased treatment
satisfaction and reduced quality of life. There
is a clear need to implement services that help
alleviate the burden of treatment experienced
by patients in order to improve their health
and well-being. Another alarming consequence
of treatment burden, particularly from a public
health perspective, was the ineﬀective use of
resources. In an era of cost eﬃciency, poor use
of health resources is particularly undesirable.
By addressing poor adherence and conse-
quently, treatment burden, it may be possible
to identify ways of minimizing the use of more
costly resources such as hospital admissions.
The World Health Organization indicates that
poor adherence to the treatment of chronic ill-
ness is a global problem averaging almost 50%
in developed countries.49 Strategies that
increase adherence are urgently needed if we
are to optimize health outcomes. However,
these strategies must take into account the
Antecedents 
Patient characteristics 
Disease conditions 
Treatment characteristics 
Family support and 
engagement 
Healthcare systems 
Attributes 
Dynamic 
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Family and carers 
Figure 2 Attributes, antecedents and consequences of treatment burden.
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subjective aspect of treatment burden and its
important cyclic nature.
Research implications
The attributes, antecedents and consequences
identiﬁed in this review also have clear implica-
tions for all health-care professionals to allevi-
ate the burden of treatment for patients. As
the perception of treatment burden could be
subjective, strategies to alleviate its impact need
to be individualized, reﬂecting the individual’s
circumstances and preferences. This review has
reinforced the fact that it is not only just health
outcomes that are important for patients and
their family, but also the way in which how
health professionals achieve those outcomes for
patients. Further, the dynamic nature of treat-
ment burden means that for any one individual
patient, their capacity to manage new and mul-
tiple treatments may vary over time. The com-
plexity of this concept can best be managed
through individualized and holistic care and
ongoing evaluation that is responsive to the
needs of each person.
The analysis has highlighted the fact that
burden can also be a result of interactions with
health-care professionals. Poor health profes-
sional–patient relationships and a lack of ade-
quate information regarding treatment were
associated with high levels of treatment bur-
den. As Moss and Crane29 argued, poor com-
munication between patients and health-care
providers about medication use may result in
the provision of multiple medications, which
could then lead to treatment burden. Health-
care professionals need to develop a relation-
ship that is sensitive to patient’s preferences
and oﬀer explanations of treatment options
that include their potential side-eﬀects. This
type of relationship will enable patients to
become more actively involved in decision
making and integrate treatment with their daily
lives, ultimately improving adherence and
treatment outcomes.
Despite the variety of settings and methods
used in the studies included in this concept
analysis, treatment burden resulting from
medication use emerged as a key theme. This
ﬁnding is not surprising given that medication
is one of the most common forms of treatment
for chronic conditions. In Australia, reports
indicate that Australians between the ages of
65 and 75 were taking an average of four medi-
cations in 2009 and will be taking, on average,
six medications by 2019.50 The ﬁndings present
clear opportunities for health professionals
who are prescribing or dispensing medications
to engage in greater discussions and improve
medication management among patients. Com-
munity pharmacists, in particular, are accessi-
ble and well placed to support medication
management, so that patients with chronic con-
ditions receive the maximum beneﬁt from their
treatment.
Interestingly, the tasks of self-management
(e.g. organizing treatment, monitoring symp-
toms, changing lifestyle) were identiﬁed as a
major source of treatment burden. Similar to
the ﬁndings of Gallacher et al.,19 our study
revealed a set of tasks associated with learning
about treatments, engaging with and organiz-
ing the treatment, altering routines and moni-
toring symptoms and progress. It is ironic that
these core tasks of self-management represent a
signiﬁcant burden for patients despite being
seen as a solution for the long-term manage-
ment of chronic illness in society. Gallacher
et al.,19 were able to clearly distinguish between
treatment burden and illness or disease burden,
suggesting that our response to chronic illness
generates a great deal of distress that is inde-
pendent of that which might be experienced
otherwise. It is not surprising that Gallacher
et al. refer to treatment burden as the ‘work’
of chronic disease management. Our study has
conﬁrmed the important role this ‘work’ plays
in generating a sense of burden. This review
identiﬁed many negative consequences of treat-
ment burden some of which may result in the
continued escalation of burden over time
because they also act as antecedents. Breaking
this cycle is important, as is the identiﬁcation
of the factors that have the greatest impact on
treatment burden and those that can be most
easily modiﬁed. Clearly, health professionals
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have a major role alongside patients and their
families in alleviating the burden associated
with the treatment of chronic illness.
Research limitations
Like any research, this review also has limita-
tions that must be considered. Only research
published in the decade between 2002 and 2011
was included in the analysis. These dates were
chosen because treatment burden is a relatively
new and evolving concept and therefore
research conducted prior to this date was
deemed inappropriate for the purposes of this
review. Furthermore, the articles used in the
concept analysis focused on selected chronic ill-
nesses known to be associated with high bur-
den of disease. We acknowledge that there may
be high levels of treatment burden associated
with other ongoing health conditions. Given
the importance of treatment burden for
patients and their family and lack of clariﬁca-
tion of the concept to date, the insights from
this review provide a valuable foundation on
which to further develop this concept.
Conclusion
Given the potential negative impacts of treat-
ing a chronic illness(s), researchers and health-
care professionals need to engage in collabora-
tive discussions and make cooperative eﬀorts
to help alleviate treatment burden in order to
optimize health outcomes. Continued research
into treatment burden, its deﬁnition, assess-
ment and impact, is needed to understand peo-
ple’s burden experience and implement
treatment that suits the realities of daily life.
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